Retatrutide Calculator

What is Retatrutide?

Retatrutide (also known as LY3437943) is a first-in-class triple receptor agonist — one of the most ambitious molecules in modern metabolic peptide research. Unlike pure GLP-1 agonists such as semaglutide or dual agonists like tirzepatide, retatrutide simultaneously activates three distinct receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This tri-receptor activation sets retatrutide apart from every other peptide currently in this class.

The GLP-1 component increases insulin secretion in a glucose-dependent manner and slows gastric emptying — both classical mechanisms that reduce appetite and caloric intake. The GIP component enhances insulin sensitivity and acts additively with GLP-1 to drive weight loss. The glucagon component, the third pillar, raises resting energy expenditure by stimulating hepatic lipolysis and producing thermogenic effects. The convergence of all three pathways produces weight loss results that are, based on current trial data, unprecedented in the pharmacological literature.

Eli Lilly is developing retatrutide through ongoing Phase II and Phase III trials (as of 2026). Phase II data published in the New England Journal of Medicine demonstrated a mean body-weight reduction of up to 24.2% at the highest dose group after 48 weeks — a figure previously achievable only through bariatric surgery. Retatrutide is not an approved medicine and remains strictly in the research phase.

For researchers working with this peptide, the Retatrutide Calculator on this page provides a practical tool for computing injection volumes and reconstitution concentrations. Retatrutide is available as a research peptide from BergdorfBio: Retatrutide at BergdorfBio.

Calculating the Retatrutide Dose

Retatrutide dosing follows a strict titration protocol designed specifically to minimize gastrointestinal side effects. Because of the triple receptor activation, the body is more sensitive to retatrutide than to simple GLP-1 agonists — a particularly gradual up-titration is therefore essential.

The starting dose is 0.5 mg per week, which is low even by the standards of this peptide class. This is not arbitrary: trial data shows that faster dose escalation leads to pronounced nausea, vomiting, and fatigue that occur far less frequently with a slower approach.

The formula for calculating injection volume — which the Retatrutide Calculator applies automatically — is:

Injection volume (mL) = Target dose (mg) ÷ Concentration (mg/mL)
Concentration = Peptide amount in vial (mg) ÷ Bacteriostatic water added (mL)

Example: A 10 mg vial reconstituted with 2 mL bacteriostatic water (BAC water) gives a concentration of 10 ÷ 2 = 5 mg/mL. To inject 0.5 mg, you draw 0.5 ÷ 5 = 0.10 mL (10 units on a U100 insulin syringe).

Injection volumes across the titration schedule (at 5 mg/mL concentration):

• 0.5 mg → 0.10 mL (10 units)
• 1 mg → 0.20 mL (20 units)
• 2 mg → 0.40 mL (40 units)
• 4 mg → 0.80 mL (80 units)
• 8 mg → 1.60 mL (160 units — requires two injections or a larger syringe)
• 12 mg → 2.40 mL (240 units — split across multiple injection sites)

At higher doses, splitting the volume across two separate injection sites is advisable to reduce local irritation. Suitable sites include the abdomen, thigh, and upper arm — always subcutaneously (just beneath the skin, not intramuscular).

Titration Schedule

The titration schedule used in Eli Lilly's Phase II clinical trials calls for dose increases every four weeks. This pacing gives the gastrointestinal tract adequate time to adapt at each level before proceeding higher.

If side effects emerge, hold the current dose for an additional four-week period before escalating further. Not all researchers reach the maximum 12 mg dose — many maintain at 4 or 8 mg once a satisfactory response is achieved.

For comparison, the Semaglutide Calculator and the Tirzepatide Calculator offer analogous titration support for the related GLP-1 peptides.

Reconstitution

Reconstituting retatrutide powder requires careful, sterile technique. The lyophilized powder is sensitive to mechanical stress — vigorous shaking can damage the peptide structure and reduce potency.

Materials needed:

• 1 vial of retatrutide (e.g., 10 mg lyophilized powder)
• Bacteriostatic water (BAC water), 2 mL
• 2 sterile needles (23–25 gauge)
• 1 insulin syringe (U100, 0.3 mL or 1 mL)
• Alcohol swabs

Step-by-step procedure:

1. Wash hands thoroughly and prepare a clean, dust-free work surface.
2. Disinfect the rubber stopper of both vials (BAC water and retatrutide) with alcohol swabs and allow to dry completely (approximately 30 seconds).
3. Draw 2 mL of BAC water into the first syringe.
4. Position the needle at an angle against the inner glass wall of the retatrutide vial so that the water runs slowly down the side — never inject directly onto the powder.
5. Gently roll the vial between your palms until the powder has fully dissolved (1–3 minutes). Do not shake.
6. Inspect the solution for particles and discoloration. A correctly reconstituted solution is clear and colorless to slightly yellowish.
7. Refrigerate the vial immediately (2–8 °C) and label it with the contents, date, and concentration.

Storage and Shelf Life

Retatrutide is significantly more stable as a lyophilized (freeze-dried) powder than as a reconstituted solution. Storage recommendations differ depending on the form:

Lyophilized powder (unopened):

• At 2–8 °C: stable for up to 24 months
• At -20 °C (deep freeze): stable for up to 36 months
• Room temperature (up to 25 °C): acceptable short-term for shipping (up to 14 days)

Reconstituted solution (after dissolving):

• At 2–8 °C (refrigerator): stable for up to 28 days
• At -20 °C: up to 3 months, though activity may decrease with repeated freeze-thaw cycles
• Room temperature: maximum 8 hours — discard after that

Important: never expose retatrutide to direct sunlight or heat sources. Always store solution vials in a light-protective container. If the solution becomes cloudy, forms particulates, or changes color, do not use it.

A common storage error is placing vials in the refrigerator door — temperature fluctuations there are greater due to frequent opening. The inner shelf (rear) provides the most stable conditions.

Side Effects and Safety

As a triple agonist, retatrutide carries a broader side effect profile than pure GLP-1 agonists. Clinical trials report the following:

Common side effects (observed in >10% of participants in Phase II trials):

• Nausea (especially in the first 4–8 weeks and after each dose increase)
• Diarrhea (watery stools, usually self-limiting)
• Vomiting (less frequent than with semaglutide, but possible)
• Reduced appetite (desired effect, but can lead to inadequate caloric intake)
• Fatigue (particularly during the up-titration phase)
• Constipation (alternation between diarrhea and constipation is possible)

Rare but serious risks:

• Pancreatitis: warning signs include persistent severe abdominal pain radiating to the back
• Gallstones: rapid weight loss increases the risk of cholecystolithiasis
• Elevated heart rate: the glucagon component can cause mild tachycardia
• Lean mass loss: rapid weight loss without adequate protein intake and resistance training can lead to muscle catabolism

Contraindications based on current research data include: personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia Type 2 (MEN 2), active pancreatitis, and severe renal or hepatic impairment.

Retatrutide is not an approved medication and is used exclusively for research purposes. Any human application is at the individual's own risk and should be conducted under medical supervision.

Combinations and Stacks

Retatrutide differs from other GLP-1 peptides in another important respect: because it already provides triple receptor activation, it is typically used as a standalone peptide in research contexts. Combining it with other GLP-1, GIP, or glucagon agonists would risk unpredictable overstimulation of the targeted receptors and is inadvisable on safety grounds.

Some researchers combine retatrutide with peptide compounds that have no GLP-1/GIP/GCG activity. In such cases the following considerations apply:

• Body composition peptides (e.g., BPC-157, TB-500): These operate via entirely different mechanisms with no direct receptor overlap. Parallel use is theoretically conceivable, but there are no controlled studies on this combination.
• Testosterone and anabolic steroids: Some researchers see potential synergy, as retatrutide reduces fat mass significantly while anabolics could counteract lean mass loss. This combination carries substantial endocrine risks and lacks any clinical support.
• Growth hormone-releasing peptides (CJC-1295, Ipamorelin): Theoretically considered for addressing lean mass loss — but no safety data exist for the combination.

Bottom line: retatrutide should generally be treated as a monotherapy in research contexts. If you are looking for a dual agonist with broader combination potential, the Tirzepatide Calculator and related information pages may be more relevant.

Frequently Asked Questions

What makes retatrutide unique compared to semaglutide and tirzepatide?

Retatrutide is the only peptide in its class to simultaneously activate GLP-1, GIP, and glucagon receptors (triple agonist). Semaglutide is a pure GLP-1 agonist; tirzepatide activates GLP-1 and GIP (dual agonist). The glucagon component in retatrutide raises basal metabolic rate and increases fat oxidation through an independent mechanism, which may explain the superior weight-reduction outcomes observed in trials.

How long does it take for retatrutide to work?

Appetite-reducing effects are often noticeable after the second or third injection. Measurable changes in body weight typically appear after 4–8 weeks. Maximum effect is expected after 24–48 weeks of continuous use, as the peptide requires slow titration before reaching therapeutic doses.

What is the half-life of retatrutide?

The terminal half-life is approximately 6 days, enabling a convenient once-weekly injection schedule. Semaglutide has a similar half-life of approximately 7 days; tirzepatide is around 5 days.

Is retatrutide approved for human use?

No. As of 2026, retatrutide is in Phase III development by Eli Lilly and has not been approved by the FDA or EMA as a medication. It is used exclusively for research purposes.

Which syringe is best for retatrutide injections?

For the starting dose (0.5 mg) and low doses up to 2 mg, 0.3 mL U100 insulin syringes are well-suited. For doses from 4 mg upward, a 1 mL syringe is more practical. At 8 mg and 12 mg, splitting the volume across two injections is recommended.

Can I freeze retatrutide?

The lyophilized powder (unopened) can be stored at -20 °C for up to 36 months. Reconstituted solutions should preferably not be frozen, as repeated freeze-thaw cycles can damage the peptide structure. If freezing is necessary, limit freeze-thaw cycles to one or two.

What should I do if I experience severe nausea after injection?

Mild nausea in the hours following injection is normal and usually subsides within a few hours. Helpful measures include: small frequent meals, a low-fat diet, adequate hydration, and avoiding strong odors. If nausea persists beyond 24 hours or is accompanied by vomiting, maintain the current dose for another week or reduce to the previous dose level.

Are there differences between research peptide retatrutide and pharmaceutical-grade material?

Pharmaceutical-grade retatrutide (used in clinical trials) is manufactured under Good Manufacturing Practice (GMP) with analytically verified purity profiles and sterile finished preparations. Research peptides can vary in purity and sterility. Choosing a supplier with transparent certificates of analysis (COA, HPLC, MS) is therefore critical.

Medical Disclaimer: All content on this page is provided for informational and research purposes only. Retatrutide is not an approved medication. The information provided here does not constitute medical advice, diagnosis, or treatment recommendation and is not a substitute for consultation with a qualified physician or healthcare professional. Human application of peptides outside clinical trials is the sole responsibility of the individual. BergdorfBio accepts no liability for any harm resulting from the improper use of research peptides.